Tamsulosin Hydrochloride Capsule
Product Images NDC 50090-5553

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 50090-5553). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500905553)

Label for Tamsulosin Hydrochloride 0.4 mg capsules by A-S Medication Solutions. The label includes NDC 50090-5553, package lot number, storage instructions to store at 68 to 77 degrees Fahrenheit and avoid excess moisture, and a count of 90 capsules. The label also notes to see package insert for dosage information and lists the manufacturer location as Libertyville, Illinois.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph showing mean plasma concentrations of Tamsulosin Hydrochloride over time following a single 0.4 mg oral dose under fasted and fed conditions. The x-axis represents time in hours (0 to 36), and the y-axis shows plasma concentration in ng/mL (0 to 25). Two curves compare concentration changes for fasted (dashed line) and fed (solid line) states across 8 subjects.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

Line graph showing mean change from baseline in total AUA symptom score over a 13-week treatment duration plus LOCF analysis, comparing Tamsulosin Hydrochloride doses of 0.4 mg and 0.8 mg with placebo. The graph illustrates symptom score reductions over time for each treatment group in a clinical study.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph titled 'Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2' showing mean change in symptom score over the duration of treatment in weeks. The x-axis represents duration of treatment (0, 1, 2, 4, 9, 13 weeks) and the y-axis shows mean change from 0 to -11. Three treatment groups are plotted: 0.8 mg (circles, solid line), 0.4 mg (triangles, dashed line), and placebo (squares, solid line). The graph shows decreasing mean symptom scores over time for both dosages compared to placebo. Sample sizes for each group at various time points are listed below the x-axis.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing mean changes in mL/sec on the y-axis versus duration of treatment in weeks on the x-axis. The graph compares three treatment groups: 0.8 mg dose, 0.4 mg dose, and placebo, plotting their mean urine flow rate changes over a 13-week treatment period plus last observation carried forward (LOCF).*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

A line graph titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' displaying the mean change in urine flow rate over weekly treatment duration. It compares three treatments: 0.8 mg, 0.4 mg, and placebo across weeks 0 to 13, showing mean change on the y-axis (mL/sec) and duration of treatment on the x-axis (weeks).*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride, showing the arrangement of atoms and bonds in the molecule including functional groups such as methoxy, sulfonamide, and hydrochloride elements.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.